Cargando…

Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream

Background: Efficacy of ruxolitinib cream, a topical Jak1/Jak2 inhibitor, was demonstrated in a phase 2 trial in patients with vitiligo. Objective: This study aimed to characterize circulating inflammatory biomarker profiles in patients who demonstrated ≥50% improvement in facial Vitiligo Area Scori...

Descripción completa

Detalles Bibliográficos
Autores principales: Howell, Michael D., Kuo, Fiona I., Rumberger, Beth, Boarder, Erika, Sun, Kang, Butler, Kathleen, Harris, John E., Grimes, Pearl, Rosmarin, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568564/
https://www.ncbi.nlm.nih.gov/pubmed/37840766
http://dx.doi.org/10.1016/j.xjidi.2023.100230
_version_ 1785119379859439616
author Howell, Michael D.
Kuo, Fiona I.
Rumberger, Beth
Boarder, Erika
Sun, Kang
Butler, Kathleen
Harris, John E.
Grimes, Pearl
Rosmarin, David
author_facet Howell, Michael D.
Kuo, Fiona I.
Rumberger, Beth
Boarder, Erika
Sun, Kang
Butler, Kathleen
Harris, John E.
Grimes, Pearl
Rosmarin, David
author_sort Howell, Michael D.
collection PubMed
description Background: Efficacy of ruxolitinib cream, a topical Jak1/Jak2 inhibitor, was demonstrated in a phase 2 trial in patients with vitiligo. Objective: This study aimed to characterize circulating inflammatory biomarker profiles in patients who demonstrated ≥50% improvement in facial Vitiligo Area Scoring Index scores by week 24 (group 1) and those who did not (group 2). Design: This was a posthoc analysis of a multicenter, randomized, double-blind, vehicle-controlled, phase 2 study in which screening was conducted between June 7, 2017 and March 21, 2018. Population: Patients aged between 18 and 75 years with vitiligo, including depigmentation affecting ≥0.5% of body surface area on the face and ≥3% of body surface area on nonfacial areas, were eligible. Intervention: Patients applied 1.5% ruxolitinib cream to lesions once or twice daily for 52 weeks. Main outcomes and measures: Patients were grouped by achievement of ≥50% improvement in facial Vitiligo Area Scoring Index at week 24. Proteomic analysis was performed on baseline serum samples. Results: Mean ± standard error facial Vitiligo Area Scoring Index in group 1 (n = 30) versus group 2 (n = 27) improved by 79.9 ± 4.0% versus 1.1 ± 7.3% and 91.9 ± 1.5% versus 25.1 ± 13.4% at weeks 24 and 52, respectively. Broad proteomic analysis revealed 76 proteins (of 1,104 tested) that were differentially expressed between groups 1 and 2 at baseline (P < 0.05). Ten distinct proteins were upregulated in group 1; 64 were elevated in group 2. Conclusion: This analysis identified potential differences between patients who achieved ≥50% improvement in facial Vitiligo Area Scoring Index at 24 weeks and those who did not that require deeper scientific interrogation and may be important in stratifying therapeutic benefit for patients with vitiligo. Trial Registration: The original study was registered at ClinicalTrials.gov, NCT03099304.
format Online
Article
Text
id pubmed-10568564
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105685642023-10-13 Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream Howell, Michael D. Kuo, Fiona I. Rumberger, Beth Boarder, Erika Sun, Kang Butler, Kathleen Harris, John E. Grimes, Pearl Rosmarin, David JID Innov Original Article Background: Efficacy of ruxolitinib cream, a topical Jak1/Jak2 inhibitor, was demonstrated in a phase 2 trial in patients with vitiligo. Objective: This study aimed to characterize circulating inflammatory biomarker profiles in patients who demonstrated ≥50% improvement in facial Vitiligo Area Scoring Index scores by week 24 (group 1) and those who did not (group 2). Design: This was a posthoc analysis of a multicenter, randomized, double-blind, vehicle-controlled, phase 2 study in which screening was conducted between June 7, 2017 and March 21, 2018. Population: Patients aged between 18 and 75 years with vitiligo, including depigmentation affecting ≥0.5% of body surface area on the face and ≥3% of body surface area on nonfacial areas, were eligible. Intervention: Patients applied 1.5% ruxolitinib cream to lesions once or twice daily for 52 weeks. Main outcomes and measures: Patients were grouped by achievement of ≥50% improvement in facial Vitiligo Area Scoring Index at week 24. Proteomic analysis was performed on baseline serum samples. Results: Mean ± standard error facial Vitiligo Area Scoring Index in group 1 (n = 30) versus group 2 (n = 27) improved by 79.9 ± 4.0% versus 1.1 ± 7.3% and 91.9 ± 1.5% versus 25.1 ± 13.4% at weeks 24 and 52, respectively. Broad proteomic analysis revealed 76 proteins (of 1,104 tested) that were differentially expressed between groups 1 and 2 at baseline (P < 0.05). Ten distinct proteins were upregulated in group 1; 64 were elevated in group 2. Conclusion: This analysis identified potential differences between patients who achieved ≥50% improvement in facial Vitiligo Area Scoring Index at 24 weeks and those who did not that require deeper scientific interrogation and may be important in stratifying therapeutic benefit for patients with vitiligo. Trial Registration: The original study was registered at ClinicalTrials.gov, NCT03099304. Elsevier 2023-09-13 /pmc/articles/PMC10568564/ /pubmed/37840766 http://dx.doi.org/10.1016/j.xjidi.2023.100230 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Howell, Michael D.
Kuo, Fiona I.
Rumberger, Beth
Boarder, Erika
Sun, Kang
Butler, Kathleen
Harris, John E.
Grimes, Pearl
Rosmarin, David
Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream
title Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream
title_full Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream
title_fullStr Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream
title_full_unstemmed Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream
title_short Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream
title_sort baseline levels of circulating inflammatory biomarkers stratify patients with vitiligo who significantly repigment after treatment with ruxolitinib cream
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568564/
https://www.ncbi.nlm.nih.gov/pubmed/37840766
http://dx.doi.org/10.1016/j.xjidi.2023.100230
work_keys_str_mv AT howellmichaeld baselinelevelsofcirculatinginflammatorybiomarkersstratifypatientswithvitiligowhosignificantlyrepigmentaftertreatmentwithruxolitinibcream
AT kuofionai baselinelevelsofcirculatinginflammatorybiomarkersstratifypatientswithvitiligowhosignificantlyrepigmentaftertreatmentwithruxolitinibcream
AT rumbergerbeth baselinelevelsofcirculatinginflammatorybiomarkersstratifypatientswithvitiligowhosignificantlyrepigmentaftertreatmentwithruxolitinibcream
AT boardererika baselinelevelsofcirculatinginflammatorybiomarkersstratifypatientswithvitiligowhosignificantlyrepigmentaftertreatmentwithruxolitinibcream
AT sunkang baselinelevelsofcirculatinginflammatorybiomarkersstratifypatientswithvitiligowhosignificantlyrepigmentaftertreatmentwithruxolitinibcream
AT butlerkathleen baselinelevelsofcirculatinginflammatorybiomarkersstratifypatientswithvitiligowhosignificantlyrepigmentaftertreatmentwithruxolitinibcream
AT harrisjohne baselinelevelsofcirculatinginflammatorybiomarkersstratifypatientswithvitiligowhosignificantlyrepigmentaftertreatmentwithruxolitinibcream
AT grimespearl baselinelevelsofcirculatinginflammatorybiomarkersstratifypatientswithvitiligowhosignificantlyrepigmentaftertreatmentwithruxolitinibcream
AT rosmarindavid baselinelevelsofcirculatinginflammatorybiomarkersstratifypatientswithvitiligowhosignificantlyrepigmentaftertreatmentwithruxolitinibcream